 |
|
 |
 |

Home > Company Index > Drugs > Drug Delivery > Emisphere Technologies, Inc.
 |
Emisphere Technologies, Inc. |
 |
 |
 |
PROFILE |
 |
Development-stage Emisphere Technologies is creating drug-delivery systems for people who literally can't stomach the treatments they need for osteoporosis, growth disorders, asthma, and other health problems. The company's drug delivery system is intended to allow the oral delivery of medicines that, for a variety of reasons, cannot currently be offered to patients in an oral form. Emisphere is focused primarily on developing a form of its anticoagulant/antithrombitic treatment for cardiovascular disease, Heparin, using this technology. The company has collaborative partnerships with Novartis, DuPont, and Eli Lilly and is also working with Regeneron Pharmaceuticals on an orally administered obesity treatment.
COMPETITION |
 |
ALZA Corporation (dossier)
AP Pharma Inc. (APPA)
Endorex Corporation (DOR)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: July
2000 Sales (mil.): 5.90
1-Yr. Sales Growth: (42.2)%
Employees: 125
Revenue per employee: $47,200.00
KEY PEOPLE |
 |
Michael M. Goldberg
CEO
Charles H. Abdalian
CFO
CONTACT INFO |
 |
765 Old Saw Mill River Rd.
Tarrytown, NY 10591
US
Phone: 914-347-2220
Fax: 914-347-2498
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |